ArticleNPJ cardiovascular health2026
Assessing the feasibility of using smartphone data to identify risk of idiopathic pulmonary arterial hypertension.
Article in NPJ cardiovascular health, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Remote exercise assessment in pulmonary hypertension.Current opinion in pulmonary medicine · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
Abstract
Idiopathic pulmonary arterial hypertension (IPAH) is a progressive, life-limiting condition often diagnosed late due to non-specific symptoms and requirement of invasive right heart catheterisation. This pilot study explores the feasibility of using real-world physical activity data from wearable devices and a smartphone app (My Heart Counts) to aid earlier detection. We analysed up to eight years of retrospective data from 109 UK participants, including patients with IPAH, disease controls, and healthy individuals. A classifier trained on pre-diagnostic activity and heart rate, distinguished individuals with IPAH from healthy and disease controls with an ROC AUC of 0.87, improving to 0.94 with in-app questionnaire input. Validation in a matched US cohort yielded an ROC AUC of 0.74. Wearable-derived metrics correlated with clinical 6MWD supporting their potential to complement traditional risk assessment. These pilot findings suggest that digital health tools may support earlier detection and remote monitoring of IPAH warranting larger scale studies.
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.